Hemostasis Today

July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Gene Nudelman: Early Hemorrhage Control Improves Patient Outcomes
Jul 10, 2026, 20:15

Gene Nudelman: Early Hemorrhage Control Improves Patient Outcomes

Gene Nudelman, CEO at Core Scientific Creations Ltd,  shared a post on LinkedIn:

“Early hemorrhage control isn’t just about stopping bleeding – it’s about improving patient outcomes.

Every minute of uncontrolled bleeding increases the risk of hemorrhagic shock, coagulopathy, organ dysfunction, greater transfusion requirements, and mortality. That’s why time to hemostasis is one of the most important factors in trauma and surgical care.

Our latest white paper explores how WoundClot supports early hemorrhage management across the continuum of care—from the point of injury and emergency departments to operating rooms, postoperative care, vascular access, and austere environments.

Key highlights include:

  • Broad-spectrum use across appropriate accessible bleeding environments
  • FDA-cleared in the U.S. as a hemostatic wound dressing and used internationally as a Class III implantable and bioresorbable surgical hemostat in over 50 countries
  • More than a decade of clinical and commercial use with no reported product-related adverse events in company post-market surveillance
  • A unique expanding gel-matrix technology that conforms to complex wounds, adheres to tissue, and helps create an effective localized hemostatic environment
  • Evidence supporting the importance of earlier hemostasis in reducing mortality and major complications

The goal isn’t simply to stop bleeding – it’s to control hemorrhage early enough to prevent avoidable deterioration.

Every minute matters. Every drop counts.”

Gene Nudelman

Stay updated with Hemostasis Today.